PAR-22-205: NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 3, 2023.
From the official notice on Grants.gov, last changed August 10, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR34
- Clinical trialsNot allowed
- Funded byNIAMS
- Median yearly award$173,503
- Typical project length2 years
- R34, Planning Grant. Planning a clinical trial: design, protocol and feasibility work before the trial itself. Other open R34 notices.
Projects funded under PAR-22-205 were run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 12 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-205 in the NIH Guide.
Key dates
| Posted | August 10, 2022 |
|---|---|
| Deadline | November 3, 2023 |
| Archived by Grants.gov | December 9, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed Re-Issue
Funded under PAR-22-205 so far
NIH funded 12 projects under PAR-22-205 in fiscal 2023 to 2025, at 8 institutions. The median yearly award was $173,503.
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before
From fiscal 2021 to 2025, Arthritis, Musculoskeletal and Skin Diseases Research (93.846) awarded $2.6 billion across 2,897 grant awards, an average of $908,766 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 104 | $104 million |
| Brigham & Womens Hospital Inc | Massachusetts | 89 | $95.7 million |
| The Regents of the University of California, San Francisco | California | 84 | $93.3 million |
| The Washington University | Missouri | 88 | $72.4 million |
| Regents of the University of Michigan | Michigan | 73 | $68.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-205 still open?
No. It closed on November 3, 2023.
Who can apply for NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed?
Closed November 3, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-205?
NIH RePORTER lists 12 projects funded under PAR-22-205 in fiscal 2023 to 2025, at 8 institutions. The most were at Univ of North Carolina Chapel Hill, University of Michigan at Ann Arbor, University of Maryland Baltimore.
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, The Regents of the University of California, San Francisco. The program made 2,897 awards worth $2.6 billion in that time.
Similar open grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)